Navigating the Biosimilar Boom:
Strategic Impacts for Specialty Pharmacy

As biosimilars continue to reshape the U.S. healthcare landscape, their market penetration has accelerated across both medical and pharmacy benefit channels. As we approach 2026, biosimilar competition has expanded to include many of the highest-cost specialty therapies, driving significant shifts in payer strategies, formulary design, and patient access. Specialty pharmacies now face both opportunities and challenges as they adapt to this rapidly evolving environment—balancing cost containment, operational efficiency, and clinical outcomes.

This session will explore the latest biosimilar market trends, with a sharp focus on their strategic implications for outpatient specialty pharmacy. Topics will include pricing dynamics, payer adoption models, manufacturer partnerships, and the evolving role of specialty pharmacy in optimizing biosimilar uptake and patient engagement.